Targeted therapies with immunotherapies in kidney cancer

The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology. During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium.  The data from KETNOTE-426 potentially redefines the standard of care in […]

read more

Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the pembrolizumab (Keytruda) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval comes two months earlier than expected and is based on the results from the open-label KEYNOTE-426 study involving 861 patients. In this study, median progression-free […]

read more

Dalantercept plus axitinib combination for advanced kidney cancer

The results from a recent phase II study comparing a combination of dalantercept plus axitinib with axitinib plus placebo for second-line treatment of advanced renal cell carcinoma (RCC) were published in the journal Cancer this month. The study involved 124 patients with clear cell RCC who had been previously treated with an angiogenesis inhibitor, such […]

read more

Patients may not be able to tolerate recommended dose of cabozantinib

A recent study published on Oncology this month suggests that renal cell carcinoma (RCC) patients may not be able to tolerate the FDA-approved dose of cabozantinib, which was determined from the METEOR and CABOSUN clinical trials. In the current trial, a median daily dose of 33.2 mg was less than that administered in the METEOR […]

read more

First immunotherapy combination of ipilimumab plus nivolumab available to patients in England

We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund. The availability of […]

read more

HIF-2α inhibitor shows promise in patients with advanced kidney cancer

A recent phase I/II clinical trial with PT2977, a hypoxia-inducible factor (HIF)-2α inhibitor, has shown encouraging anti-tumour activity with a favourable safety profile in patients with previously-treated advanced renal cell carcinoma (RCC). Of the 55 patients who were treated with the HIF-2α inhibitor, 12 patients (22%) had a confirmed partial response. The study is still […]

read more
Showing 1 to 6 of 564 results
  TOP